Original research
par
Martin, Emily M. et al
Date de publication
2025
Géographie
USA
Langue de la ressource
English
Texte disponible en version intégrale
Non
Open Access / OK to Reproduce
Non
Évalué par des pairs
Yes
L’objectif
The aim of this paper is to examine known and potential wound-associated agents’ (xylazine, levamisole, medetomidine) prevalence in Maryland's unregulated drug supply.
Constatations/points à retenir
Xylazine was detected in 33.4 % of samples and primarily co-occurred with fentanyl; heroin and related compounds; and other opioids, stimulants, and anesthetics. Xylazine's prevalence decreased over time and varied geographically. Levamisole and medetomidine occurred in 1.9 % and 0.7 % of samples respectively with no significant co-occurrence.
La conception ou méthodologie de recherche
Using data from Maryland's statewide drug checking program, Rapid Analysis of Drugs (RAD), this paper discusses samples that were voluntarily provided at participating syringe service programs and analyzed at the National Institute of Standards and Technology between October 2021 and October 2023 (N= 2,210). We calculated prevalence and chi-square significance to assess co-occurrence of wound-associated agents and other substances and evaluated xylazine's prevalence over time.
Mots clés
Drug checking
Harm reduction
Illegal drugs
Overdose
Xylazine
